MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

How is VYJUVEK's Commercial Performance Shaping Krystal Biotech's Outlook

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What are the Major Headwinds and Tailwinds Shaping the Biotech Sector in 2026

1 months ago

What's Driving Paycom's Recent Performance and Cautious Outlook

4 weeks ago

What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook

1 months ago

Is EverPass Media Revolutionizing Commercial Sports Distribution

1 week ago

Could This Under-the-Radar Healthcare Stock Set You Up for Life?

Krystal Biotech maintains a positive growth outlook as it prepares to potentially launch multiple new products over the next few years. The company's core market positioning remains a key driver for i...

KRYS

Stock News•2 weeks ago

Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Journey Medical (DERM) Q4 2025 results require comparison against Wall Street estimates and year-ago figures to fully assess business performance for the quarter.

DERM

Stock News•3 weeks ago

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) shares fell 11.5% over the 30 days following its last earnings report, leaving investors to assess the stock's near-term trajectory.

KRYS

Stock News•1 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech reported $107.1 million in 4Q VYJUVEK revenue, contributing to $730.3 million since launch, while ending the quarter with $955.9 million in cash and investments.

KRYS